ethyl 1-benzyl-5-methyl-1,2,3,6-tetrahydropyridine-4-carboxylate | 1254328-02-3

• 分子结构分类: 有机化合物 - 生物碱及其衍生物
• 英文名称: ethyl 1-benzyl-5-methyl-1,2,3,6-tetrahydropyridine-4-carboxylate
• 英文别名: 4-Pyridinecarboxylic acid, 1,2,3,6-tetrahydro-5-methyl-1-(phenylmethyl)-, ethyl ester；ethyl 1-benzyl-5-methyl-3,6-dihydro-2H-pyridine-4-carboxylate
• CAS: 1254328-02-3
• 化学式: C₁₆H₂₁NO₂
• 分子量: 259.348
• InChiKey: PIHFWZTVGIJVBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 1-benzyl-5-methyl-1,2,3,6-tetrahydropyridine-4-carboxylate 在 1-氯乙基氯甲酸酯 、 甲醇 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 2.0h， 生成 ethyl 5-methyl-1,2,3,6-tetrahydropyridine-4-carboxylate
  参考文献：
  名称：

  Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization

  摘要：

  We report herein the first systematic exploration of inhibitors of the mitotic kinase Nek2. Starting from HTS hit aminopyrazine 2, compounds with improved activity were identified using structure-based design. Our structural biology investigations reveal two notable observations. First, 2 and related compounds bind to an unusual, inactive conformation of the kinase which to the best of our knowledge has not been reported for other types of kinase inhibitors. Second, a phenylalanine residue at the center of the ATP pocket strongly affects the ability of the inhibitor to bind to the protein. The implications of these observations are discussed, and the work described here defines key features for potent and selective Nek2 inhibition, which will aid the identification of more advanced inhibitors of Nek2.

  DOI：

  10.1021/jm1008727
• 作为产物：
  描述：

  1-苄基-3-氧杂-4-哌啶甲酸乙酯 在 四(三苯基膦)钯 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 、 甲苯 为溶剂， 生成 ethyl 1-benzyl-5-methyl-1,2,3,6-tetrahydropyridine-4-carboxylate
  参考文献：
  名称：

  Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization

  摘要：

  We report herein the first systematic exploration of inhibitors of the mitotic kinase Nek2. Starting from HTS hit aminopyrazine 2, compounds with improved activity were identified using structure-based design. Our structural biology investigations reveal two notable observations. First, 2 and related compounds bind to an unusual, inactive conformation of the kinase which to the best of our knowledge has not been reported for other types of kinase inhibitors. Second, a phenylalanine residue at the center of the ATP pocket strongly affects the ability of the inhibitor to bind to the protein. The implications of these observations are discussed, and the work described here defines key features for potent and selective Nek2 inhibition, which will aid the identification of more advanced inhibitors of Nek2.

  DOI：

  10.1021/jm1008727

文献信息

• SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD
  申请人：Cheng T. W. Peter

  公开号：US20070287713A1

  公开（公告）日：2007-12-13

  wherein Z 1 is (CH 2 ) q or C═O; Z 2 is (CH 2 ) p or C═O; D is —CH═ or C═O or (CH 2 ) m where m is 0, 1, 2 or 3; n=0, 1 or 2; p=1 or 2; q=0, 1 or 2; Q is C or N; A is (CH 2 ) x where x is 1 to 5, or A is (CH 2 ) x 1 , where x 1 is 1 to 5 with an alkenyl bond or an alkynyl bond embedded anywhere in the chain, or A is —(CH 2 ) x 2 —O—(CH 2 ) x 3 — where x 2 is 0 to 5 and x 3 is 0 to 5, provided that at least one of x 2 and x 3 is other than 0; B is a bond or is (CH 2 ) x 4 where x 4 is 1 to 5; X is CH or N; X 2 is C, N, O or S; X 3 is C, N, O or S; X 4 is C, N, O or S; X 5 is C, N, O or S; X 6 is C, N, O or S; provided that at least one of X 2 , X 3 , X 4 X 5 and X 6 is N; and at least one of X 2 , X 3 , X 4 X 5 and X 6 is C. R 1 is H or alkyl; R 2 is H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; R 2a , R 2b and R 2c may be the same or different and are selected from H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; and R 3 , E, Z and Y are as defined herein.

  其中Z1为(CH2)q或C═O；Z2为( )p或C═O；D为—CH═或C═O或( )m，其中m为0、1、2或3；n=0、1或2；p=1或2；q=0、1或2；Q为C或N；A为( )x，其中x为1到5，或A为( )x1，其中x1为1到5，具有烯丙基键或炔基键嵌入链中的任何位置，或A为—( )x2—O—( )x3—，其中x2为0到5，x3为0到5，前提是x2和x3中至少有一个不为0；B为键或( )x4，其中x4为1到5；X为CH或N；X2、X3、X4、X5和X6为C、N、O或S；前提是X2、X3、X4、X5和X6中至少有一个为N；并且X2、X3、X4、X5和X6中至少有一个为C。R1为H或烷基；R2为H、烷基、烷氧基、卤素、氨基、取代氨基或氰基；R2a、R2b和R2c可以相同也可以不同，选择自H、烷基、烷氧基、卤素、氨基、取代氨基或氰基；而R3、E、Z和Y的定义如前所述。
• NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
  申请人：AbbVie Inc.

  公开号：EP3636643A1

  公开（公告）日：2020-04-15

  The invention provides compounds of the following formula, pharmaceutically acceptable salts thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

  本发明提供了下式化合物及其药学上可接受的盐类，其中变量在此定义。本发明的化合物可用于治疗免疫学疾病。
• Nuclear receptor modulators
  申请人：AbbVie Inc.

  公开号：US10106501B2

  公开（公告）日：2018-10-23

  The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

  本发明提供了式 (I) 的化合物 其药学上可接受的盐类，其中变量在本文中定义。本发明的化合物可用于治疗免疫学疾病。
• NUCLEAR RECEPTOR MODULATORS
  申请人：AbbVie Inc.

  公开号：EP3307734A1

  公开（公告）日：2018-04-18
• US7951793B2
  申请人：——

  公开号：US7951793B2

  公开（公告）日：2011-05-31